What proportion of lipitor's revenue was lost due to generic competition?

How much revenue did Pfizer lose when Lipitor lost exclusivity?

Pfizer's U.S. sales of Lipitor dropped from $7.9 billion in 2011 to $1.6 billion in 2012, the first full year after generic atorvastatin entered the market. This represented a roughly 80% revenue decline in the United States.

How quickly did sales fall after generics launched?

Generic atorvastatin reached the market in November 2011. By the end of the first quarter of 2012, branded Lipitor's U.S. prescription share had already fallen below 10%. Monthly revenue losses exceeded $600 million within weeks of generic entry.

Did the loss occur evenly across all markets?

No. In countries with slower generic uptake or stricter substitution rules, Pfizer retained higher branded shares for longer. Europe saw a more gradual erosion, while the U.S. experienced the sharpest single-quarter drop due to automatic generic substitution at pharmacies.

What role did authorized generics play?

Pfizer launched its own authorized generic through Watson Pharmaceuticals. This strategy captured some of the price erosion but still transferred most of the volume to lower-priced copies. The arrangement reduced Pfizer's net revenue per pill while slowing the total loss of market share.

When did Lipitor's key U.S. patent expire?

The primary composition-of-matter patent expired on 30 November 2011. A pediatric exclusivity extension had already pushed the effective loss-of-exclusivity date to that point after earlier litigation.

Why did some analysts expect a softer revenue cliff?

Pre-launch forecasts assumed slower generic penetration because of Lipitor's brand strength and physician loyalty. Actual substitution rates exceeded those models once payers and pharmacy benefit managers mandated generic use, producing steeper losses than projected.

Did the loss affect Pfizer's overall financial guidance?

Yes. Pfizer lowered its 2012 earnings forecast by roughly $3.3 billion to account for the Lipitor erosion. The company cited the patent expiry as the single largest driver of its projected revenue decline that year.

Can similar revenue shocks happen to other blockbusters?

Later launches such as Eliquis and Xarelto have faced biosimilar or generic challenges, but staggered loss-of-exclusivity dates across regions and additional indications have softened the impact compared with Lipitor's single, abrupt U.S. cliff.